Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.67
XNPT's Cash to Debt is ranked lower than
73% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. XNPT: 1.67 )
Ranked among companies with meaningful Cash to Debt only.
XNPT' s 10-Year Cash to Debt Range
Min: 1.67  Med: 10000.00 Max: No Debt
Current: 1.67
Equity to Asset 0.34
XNPT's Equity to Asset is ranked lower than
81% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. XNPT: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
XNPT' s 10-Year Equity to Asset Range
Min: -1.59  Med: 0.73 Max: 0.88
Current: 0.34
-1.59
0.88
F-Score: 5
Z-Score: -1.51
M-Score: -1.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -95.90
XNPT's Operating margin (%) is ranked lower than
54% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. XNPT: -95.90 )
Ranked among companies with meaningful Operating margin (%) only.
XNPT' s 10-Year Operating margin (%) Range
Min: -5504.8  Med: -361.96 Max: 18.25
Current: -95.9
-5504.8
18.25
Net-margin (%) -97.30
XNPT's Net-margin (%) is ranked lower than
55% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. XNPT: -97.30 )
Ranked among companies with meaningful Net-margin (%) only.
XNPT' s 10-Year Net-margin (%) Range
Min: -4876  Med: -360.18 Max: 24.77
Current: -97.3
-4876
24.77
ROE (%) -51.51
XNPT's ROE (%) is ranked lower than
64% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. XNPT: -51.51 )
Ranked among companies with meaningful ROE (%) only.
XNPT' s 10-Year ROE (%) Range
Min: -93.4  Med: -53.23 Max: 27
Current: -51.51
-93.4
27
ROA (%) -32.40
XNPT's ROA (%) is ranked lower than
56% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. XNPT: -32.40 )
Ranked among companies with meaningful ROA (%) only.
XNPT' s 10-Year ROA (%) Range
Min: -127.82  Med: -49.43 Max: 18.7
Current: -32.4
-127.82
18.7
ROC (Joel Greenblatt) (%) -2037.48
XNPT's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. XNPT: -2037.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XNPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2671.31  Med: -835.20 Max: 561.29
Current: -2037.48
-2671.31
561.29
Revenue Growth (3Y)(%) -14.50
XNPT's Revenue Growth (3Y)(%) is ranked lower than
64% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. XNPT: -14.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XNPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -72.6  Med: -14.50 Max: 126.3
Current: -14.5
-72.6
126.3
EBITDA Growth (3Y)(%) -2.40
XNPT's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. XNPT: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XNPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.3  Med: -15.60 Max: -2.4
Current: -2.4
-54.3
-2.4
EPS Growth (3Y)(%) -4.80
XNPT's EPS Growth (3Y)(%) is ranked higher than
53% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. XNPT: -4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XNPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.3  Med: -12.40 Max: -4.8
Current: -4.8
-52.3
-4.8
» XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

XNPT Guru Trades in Q2 2014

John Burbank 17,817 sh (New)
Paul Tudor Jones Sold Out
PRIMECAP Management 104,000 sh (-18.75%)
» More
Q3 2014

XNPT Guru Trades in Q3 2014

John Burbank Sold Out
PRIMECAP Management 91,000 sh (-12.50%)
» More
Q4 2014

XNPT Guru Trades in Q4 2014

Paul Tudor Jones 18,549 sh (New)
Charles Brandes 19,700 sh (New)
PRIMECAP Management 91,000 sh (unchged)
» More
Q1 2015

XNPT Guru Trades in Q1 2015

PRIMECAP Management 91,000 sh (unchged)
Charles Brandes 19,700 sh (unchged)
Paul Tudor Jones 17,570 sh (-5.28%)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.37
XNPT's P/B is ranked lower than
62% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. XNPT: 6.37 )
Ranked among companies with meaningful P/B only.
XNPT' s 10-Year P/B Range
Min: 1.71  Med: 4.02 Max: 13.19
Current: 6.37
1.71
13.19
P/S 9.07
XNPT's P/S is ranked higher than
56% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. XNPT: 9.07 )
Ranked among companies with meaningful P/S only.
XNPT' s 10-Year P/S Range
Min: 2.65  Med: 14.26 Max: 111.17
Current: 9.07
2.65
111.17
Current Ratio 12.40
XNPT's Current Ratio is ranked higher than
82% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. XNPT: 12.40 )
Ranked among companies with meaningful Current Ratio only.
XNPT' s 10-Year Current Ratio Range
Min: 2.31  Med: 7.52 Max: 12.4
Current: 12.4
2.31
12.4
Quick Ratio 12.28
XNPT's Quick Ratio is ranked higher than
82% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. XNPT: 12.28 )
Ranked among companies with meaningful Quick Ratio only.
XNPT' s 10-Year Quick Ratio Range
Min: 2.31  Med: 7.52 Max: 12.28
Current: 12.28
2.31
12.28
Days Inventory 249.57
XNPT's Days Inventory is ranked lower than
81% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. XNPT: 249.57 )
Ranked among companies with meaningful Days Inventory only.
XNPT' s 10-Year Days Inventory Range
Min: 196.85  Med: 216.96 Max: 237.06
Current: 249.57
196.85
237.06
Days Sales Outstanding 20.84
XNPT's Days Sales Outstanding is ranked higher than
83% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. XNPT: 20.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
XNPT' s 10-Year Days Sales Outstanding Range
Min: 4.22  Med: 43.11 Max: 96.22
Current: 20.84
4.22
96.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.10
XNPT's Price/Net Cash is ranked lower than
57% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. XNPT: 10.10 )
Ranked among companies with meaningful Price/Net Cash only.
XNPT' s 10-Year Price/Net Cash Range
Min: 2.06  Med: 5.09 Max: 16.33
Current: 10.1
2.06
16.33
Price/Net Current Asset Value 8.45
XNPT's Price/Net Current Asset Value is ranked lower than
54% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. XNPT: 8.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
XNPT' s 10-Year Price/Net Current Asset Value Range
Min: 1.97  Med: 4.84 Max: 14.92
Current: 8.45
1.97
14.92
Price/Tangible Book 6.32
XNPT's Price/Tangible Book is ranked lower than
53% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. XNPT: 6.32 )
Ranked among companies with meaningful Price/Tangible Book only.
XNPT' s 10-Year Price/Tangible Book Range
Min: 1.8  Med: 4.27 Max: 12.9
Current: 6.32
1.8
12.9
Price/Median PS Value 0.63
XNPT's Price/Median PS Value is ranked higher than
82% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. XNPT: 0.63 )
Ranked among companies with meaningful Price/Median PS Value only.
XNPT' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.05 Max: 6.6
Current: 0.63
0.21
6.6
Earnings Yield (Greenblatt) (%) -12.49
XNPT's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. XNPT: -12.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XNPT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -12.63  Med: 1.70 Max: 4492.4
Current: -12.49
-12.63
4492.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LMW.Germany,
XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. With respect to AP, it has decided to terminate further investment in AP as a treatment for spasticity in patients with MS; however, given a previous, successful Phase 2 clinical trial of AP as a potential treatment for spasticity in spinal cord injury patients. XP21279, in the primary analysis of the trial, the improvement with XP21279/carbidopa dosed three times per day was not statistically good than the improvement seen with optimized Sinemet dosed four or five times per day during the double-blind phase of the trial. It has discussed the results of this trial with experts in Parkinson's disease and with regulatory authorities. As a result, it plans to continue development of XP21279 to the extent its resources permit or it enters into collaboration with a third party. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as govern
» More Articles for XNPT

Headlines

Articles On GuruFocus.com
comment on XNPT Mar 15 2013 
comment on XNPT Mar 06 2013 
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
XenoPort Reports Second Quarter Financial Results Aug 05 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XenoPort to Release Second Quarter Financial Results on August 5, 2015 Jul 27 2015
XenoPort to Release Second Quarter Financial Results on August 5, 2015 Jul 27 2015
XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use... Jun 25 2015
3 Pharmaceutical Stocks to Sell Now Jun 25 2015
XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use... Jun 25 2015
HORIZANT (gabapentin enacarbil) Included in New Expert Recommendations on Prevention and Treatment... Jun 08 2015
HORIZANT (gabapentin enacarbil) Included in New Expert Recommendations on Prevention and Treatment... Jun 08 2015
XenoPort to Present New Pooled Data Analyses on HORIZANT (gabapentin enacarbil) at the 2015 SLEEP... Jun 02 2015
XenoPort to Present New Pooled Data Analyses on HORIZANT (gabapentin enacarbil) at the 2015 SLEEP... Jun 02 2015
XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... May 22 2015
XenoPort to Present at the Jefferies 2015 Global Healthcare Conference May 18 2015
XenoPort to Present at the Jefferies 2015 Global Healthcare Conference May 18 2015
XENOPORT INC Financials May 15 2015
10-Q for XenoPort, Inc. May 09 2015
XenoPort Q1 Loss Wider-than-Expected; Revenues Miss - Analyst Blog May 07 2015
XENOPORT INC Files SEC form 10-Q, Quarterly Report May 07 2015
XenoPort to Present New HORIZANT (gabapentin enacarbil) Data at the American Pain Society 34th... May 07 2015
XenoPort to Present New HORIZANT (gabapentin enacarbil) Data at the American Pain Society 34th... May 07 2015
XenoPort reports 1Q loss May 06 2015
Xenoport Inc Earnings Call scheduled for 5:00 pm ET today May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK